AstraZeneca Invites Partners to Explore Integrated Traditional Chinese and Western Medicine Innovation Ecosystem in Chengdu

The macro backdrop of the post-pandemic era, coupled with the inaugural year of the 14th Five-Year Plan, has further fueled the “development journey” of Traditional Chinese Medicine (TCM); meanwhile, the surge in digital technologies such as the Internet of Things (IoT), the internet, big data, and artificial intelligence has provided a potent catalyst for the innovative development of TCM.

By applying digital technologies such as the Internet of Things (IoT) and the internet to various aspects of healthcare—including disease prevention, TCM diagnosis and treatment, pharmaceutical services, and post-consultation management—the efficiency of TCM medical services has been enhanced, the diagnostic and treatment burden on physicians has been reduced, and patients’ healthcare experiences have been significantly improved. It is important to note that the integration of emerging technologies into Traditional Chinese Medicine (TCM) should be approached with case-by-case analysis rather than a “one-size-fits-all” strategy, avoiding the forced migration of clinical scenarios that are inherently more suitable for offline settings to online platforms.

The integration of Traditional Chinese Medicine (TCM) with digital technology is an inevitable move in line with the trends of the times, while the combination of TCM and Western medicine is a natural outcome of the convergence between Chinese and foreign medical practices. The approach of “integrating and concurrently applying TCM and Western medicine” adopted during the COVID-19 pandemic control serves as a vivid demonstration of TCM’s principle of “preserving its essence while upholding integrity and pursuing innovation.”

An industry discourse on the modernization trajectory of traditional Chinese medicine (TCM) and the future prospects of integrated Chinese and Western medicine is now taking shape. On the 27th and 28th of this month,The 2021 Western Smart Healthcare Industry Summit, themed “Ecological Integration, Co-Creating a Winning Future,” hosted by the China Pharmaceutical Enterprise Management Association, co-organized by the Chengdu High-Tech Zone Administrative Committee, and undertaken by AstraZeneca and EYJ Manager, will be grandly launched in the Chengdu High-Tech Zone. As one of the summit’s events, the Win-Win Future Industry Forum, themed “TCM Innovation and Integration of Traditional Chinese and Western Medicine,” will be held on the afternoon of the 28th.At this sub-forum, AstraZeneca will invite cross-sector partners from government, industry, academia, research, healthcare, and investment communities to deeply connect and aggregate multi-party resources through offline roadshows, interpretations by authoritative experts, and roundtable discussions. This initiative aims to promote the integration of Traditional Chinese Medicine (TCM) and Western medicine, and to jointly build a smart healthcare ecosystem platform characterized by the combination of TCM and Western medicine.

The conference agenda is as follows:

The “Win-Win Future Industry Forum,” themed “TCM Innovation and Integration of Traditional Chinese and Western Medicine,” serves not only as a platform for exchange, collaboration, and advocacy among stakeholders in the traditional Chinese medicine (TCM) and Western medicine industries, but also as a special invitation to attract more participants into the ecosystem. In terms of scale and stature, this industry summit is unparalleled in both depth and breadth.

Let’s start with the depth of the content.Industry leaders will focus onClinical Value of Traditional Chinese Medicine, TCM CRO, Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment, Integrated Traditional Chinese and Western Medicine RehabilitationFocus on key issues to spark a “brainstorming” session on the development mechanisms and future opportunities of the traditional Chinese medicine (TCM) big health industry.

The forum also features a roundtable session focused on current hot topics in the integrated traditional Chinese and Western medicine industry, bringing together cutting-edge industry insights, deep resource connections, and corporate development needs in one setting. This aims to address the articulation of capital investment logic, the expression of innovative enterprises’ needs for a supportive ecosystem, and the assessment of policy trends.

Revisiting the Breadth of Coverage.The forum centered on “TCM Innovation and Integration of Traditional Chinese and Western Medicine,” coveringGovernment, Industry, Academia, Research, Healthcare, and InvestmentStakeholders from all sectors are striving to fully promote cross-industry exchange and interaction, thereby building a more comprehensive innovation ecosystem for the traditional Chinese medicine (TCM) and integrated TCM-Western medicine industries.

This forum has invited numerous industry leaders to conduct an in-depth exploration of the opportunities and challenges on the path of innovation in Traditional Chinese Medicine (TCM). It will also engage in systematic discussions with leaders from Sichuan Provincial authorities on TCM, presidents of renowned hospitals across China, international pharmaceutical companies, and leading figures from innovative enterprises on the most cutting-edge application scenarios of both TCM and Western medicine.

Attendees include:

Zhao Junning, President of Sichuan Academy of Chinese Medicine Sciences

Yang Dianxing, President of the Sichuan Association of Traditional Chinese Medicine

An Qu, President of Sichuan Hospital Association

Peng Cheng, Vice President of Chengdu University of Traditional Chinese Medicine

Wang Chao, Party Secretary of Sichuan Provincial Hospital of Integrated Traditional Chinese and Western Medicine

Chen Qiu, Director of the Department of Endocrinology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Che Guowei, Vice President of the Pulmonary Rehabilitation Committee of the World Federation of Chinese Medicine Societies, Professor at West China Hospital

Lei JuanDeputy Director, West China Hospital Center for Technology Transfer of Pharmaceutical Innovations

Song Yi, Head of the Quality Inspection Department, Pharmacy Department, West China Hospital

Gong Dequan, Chairman of Luye Life Sciences (Chengdu) Group Co., Ltd.

Wang Shuaishuai, General Manager of Haibote Pharmaceutical Technology Co., Ltd.

Zhang Yiguan, Chairman of Sichuan Yunshi New Medical Laboratory Co., Ltd.

Zhang Lehui, Operating Partner at Changling Capital

Lai Minglong, General Manager of AstraZeneca China

Yin Min, General Manager of AstraZeneca China's Oncology Business Unit

More distinguished guests to be announced—stay tuned...

To ensure the inheritance and development of Traditional Chinese Medicine (TCM), share medical discourse power with Western medicine, and achieve genuine integration of TCM and Western medicine, it is essential to break free from self-imposed constraints, foster innovation, and escape the vicious cycle of “having outstanding individuals but lacking collaborative research.” AstraZeneca also hopes to leverage this conference to build a platform for exchange and collaboration among government, industry, academia, research institutions, healthcare providers, and investors in the integrated TCM-Western medicine sector, jointly exploring the possibilities of integrating TCM with Western medicine.

In recent years, Sichuan Province has accelerated the high-quality development of its traditional Chinese medicine (TCM) industry and the construction of a TCM powerhouse, striving to enhance the innovation capacity and competitiveness of the sector. Leveraging this industrial advantage, and aiming to empower partners more comprehensively while accelerating the translation of TCM projects, AstraZeneca and its partners have established their presence in Chengdu to buildModern Innovation Center for Integrated Traditional Chinese and Western Medicine,It aims to integrate its innovative model with local industrial development, evolving into a key hub for exploring the integration of traditional Chinese medicine and Western medicine.

The Modern Innovation Center for Integrated Traditional Chinese and Western Medicine will officially open during this industry summit, while AstraZeneca’s China Western Headquarters in the Chengdu High-Tech Zone will also be formally inaugurated.On November 5, 2020, Chengdu High-Tech Zone signed an investment cooperation agreement with AstraZeneca to establish its Western China Headquarters. Concurrently, the Modern Innovation Center for Integrated Traditional Chinese and Western Medicine was launched, providing end-to-end services—including project development, enterprise incubation, and industry cultivation—for entrepreneurial and innovative initiatives in traditional Chinese medicine.

The Modernization Innovation Center for Integrated Traditional Chinese and Western Medicine will become the fourth innovation center to officially open, following the China Health IoT Innovation Center in Wuxi, the Primary Care Smart Healthcare Innovation Center in Beijing, and the Digital Healthcare Innovation Center in Hangzhou. Leveraging Chengdu’s foundational strengths in the traditional Chinese medicine (TCM) industry, the Modernization Innovation Center for Integrated Traditional Chinese and Western Medicine will vigorously promote upstream and downstream collaboration upon its launch, incubate innovative integrated diagnostic and therapeutic solutions featuring TCM elements, and drive the development of the TCM industry.

“Patient-Centered”: Pursuing Three Major Modernized Solutions for the Integration of Traditional Chinese and Western Medicine.The Integrated Traditional Chinese and Western Medicine Modernization Innovation Center is currently seeking innovative solutions with core technological barriers and promising market applications from TCM-WM integration enterprises, teams, and research institutions at all stages, both domestically and internationally. We cordially invite them to join the innovation ecosystem jointly established by AstraZeneca, its partners, and local governments, to foster collaborative development. The Center primarily focuses on the following three key areas:

It is understood that the Modern Innovation Center for Integrated Traditional Chinese and Western Medicine will center on patient needs, focus on the integration of traditional Chinese and Western medicine, and leverage collaborative efforts from government, industry, academia, research institutions, healthcare providers, and investors, throughExpert co-development and industry co-creation provide partners with richer clinical application scenarios, medical and research support, expert guidance, and omni-channel commercialization coverage., enabling resident partners to share AstraZeneca’s ecosystem resources and establish a win-win business collaboration model.

graduallyIn the process of transforming from a traditional pharmaceutical company into a platform-based enterprise, AstraZeneca has consistently centered its efforts on meeting the needs of patients’ whole-course disease management.It has established an innovation ecosystem integrating three key components: an Innovation Center, an Innovation Industrial Park, and an Industry Fund. Within this ecosystem, the China Smart Health Innovation Center platform, jointly built by AstraZeneca and its partners, will play a pivotal role.Leveraging regional industrial strengths, the China Smart Health Innovation Center has planned eight innovation centers across China, each featuring local industrial characteristics, of which4Innovation Center Officially Opens, at10Yuehe11The biological diagnostics innovation center in Guangzhou and the medical AI innovation center in Shanghai will also be unveiled. Currently, these regional innovation centers are extensively soliciting innovative solutions from startups, research institutes, and healthcare institutions.

As traditional Chinese medicine (TCM) enters a critical period of transformation and upgrading, all colleagues deeply engaged in the TCM industry will witness its rebirth in this new era. Hereby, you are welcome to register for the “Win-Win Future Industry Forum: TCM Innovation and Integration of Traditional Chinese and Western Medicine.” We also sincerely invite our partners to join AstraZeneca’s “Innovative Healthcare Ecosystem Circle” to contribute to the cause of medical innovation in China.

Registration Method: Please scan the QR code below, complete the required information, and you will be able to participate in the Win-Win Future Industry Forum and submit your application for collaboration with the Modernization Innovation Center for Integrated Traditional Chinese and Western Medicine.

Meeting Time: Afternoon of September 28, 2021

Venue: Three Gorges Hall, 8th Floor, Building 11 (E11), Biopharmaceutical Innovation Incubation Park, No. 16 Hemin Street, Chengdu High-Tech Zone